Varian Medical Systems Inc

Varian Medical Systems — Q4 FY2019 Earnings Presentation

34 slides from Varian Medical Systems's earnings presentation, Oct 23, 2019

  1. Slide 1: Fourth Quarter Fiscal Year 2019

    Slide 1: Fourth Quarter Fiscal Year 2019

    Fourth Quarter Fiscal Year 2019 October 23, 2019 Investor Relations

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking Statements Except for historical information, this presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. S

  3. Slide 3: Agenda: Q4 FY 2019 earnings

    Slide 3: Agenda: Q4 FY 2019 earnings

    Agenda Q4 FY 2019 earnings 1. Fourth Quarter and Full Year Results 2. Total Company Performance 3. Segment Performance 4. FY 2020 Guidance 5. Appendix VARIAN CONFIDENTIAL/ PROPRIETARY: DISCLOSED SOLELY FOR IMMEDIATE RECIPIENT ONLY

  4. Slide 4: Q4 FY 2019 key financial metrics

    Slide 4: Q4 FY 2019 key financial metrics

    Q4 FY 2019 key financial metrics $M Q4 Y/Y FY19 Y/Y Oncology Orders1 $1,137 7% $3,398 9% • Two consecutive fiscal years of double-digit revenue growth and 9 percent Oncology Revenues $879 10% $3,225 10% orders growth Oncology $820 8% $3,062 11% Proton Solutions $42 (9%) $144 (3%) • Core business pow

  5. Slide 5: Long-term growth and value creation strategy

    Slide 5: Long-term growth and value creation strategy

    Long-term growth and value creation strategy Focusing on these Strategic enablers will deliver core business growth, global expansion and new opportunities Innovate in radiation therapy Leverage artificial intelligence, machine learning and Global Leader cloud solutions Global Leader in in Radiation

  6. Slide 6: Executing on long-term growth strategy

    Slide 6: Executing on long-term growth strategy

    Executing on long-term growth strategy Innovate Leverage Grow Artificial Intelligence, Machine Learning, in Radiation Therapy Emerging Businesses and Technologies and Cloud Solutions KEY METRICS KEY METRICS KEY METRICS • Global market leader • Software revenues grew +10% • Interventional oncology re

  7. Slide 7: Varian linac net installed base

    Slide 7: Varian linac net installed base

    Varian linac net installed base Installed base growth Varian strengthened its global leadership in radiation therapy 8,496 • Net installed base grew +5% or 439 units, driving future recurring software and services revenues • All three geographies grew respective installed +439 base in the fourth qua

  8. Slide 8: Key wins

    Slide 8: Key wins

    Key wins Americas EMEA APAC University of Rochester 21st Century Oncology India – Tata Trusts Amsterdam UMC 2 TrueBeams, RapidArc, 1 Edge and 13 TrueBeam systems 6 Ethos systems Gating, and Upgrades 13 TrueBeam systems China Korea 10 Halcyon systems 4 VitalBeam systems McKesson Specialty Health 1 Ha

  9. Slide 9: Total Company Performance

    Slide 9: Total Company Performance

    Total Company Performance varian

  10. Slide 10: Total company results (GAAP)

    Slide 10: Total company results (GAAP)

    Total company results (GAAP) Key P&L financial metrics VARIAN • Revenues grew double digits driven by strength $M Q4 FY19 Y/Y FY19 Y/Y across our portfolio Gross Orders $1,185 10% $3,569 13% Revenues $879 10% $3,225 10% • R&D growth driven by investments in software, adaptive radiotherapy, FLASH and

  11. Slide 11: Total company results (non-GAAP)

    Slide 11: Total company results (non-GAAP)

    Total company results (non-GAAP) Key P&L financial metrics VARIAN • Revenues grew double digits driven by strength $M Q4 FY19 Y/Y FY19 Y/Y across our portfolio; strong orders growth in both Gross Orders $1,185 10% $3,569 13% Oncology Systems and Proton Solutions Revenues $879 10% $3,225 10% • Gross

  12. Slide 12: Total company results: balance sheet and cash flow metrics

    Slide 12: Total company results: balance sheet and cash flow metrics

    Total company results Key balance sheet and cash flow metrics • Cash & Cash Equivalents of $531 million Cash & Cash Equivalents ($M) Total Debt ($M) +5% Y/Y +$412M Y/Y • Total Debt of $412 million $700 $500 $400 • Q4 FY19 $600 − Cash Flow from Operations of $118 million $300 − Capital Expenditures o

  13. Slide 13: Capital allocation priorities

    Slide 13: Capital allocation priorities

    Capital allocation priorities Q4 update Long-term value creation strategy that includes balancing growth, profitability and liquidity Organic R&D and Capital • Innovations in FLASH technology, software capability, adaptive radiotherapy, and infrastructure Investments Inorganic • Investing to build o

  14. Slide 14: Segment Performance

    Slide 14: Segment Performance

    Segment Performance varian

  15. Slide 15: Oncology Systems segment (GAAP)

    Slide 15: Oncology Systems segment (GAAP)

    Oncology Systems segment (GAAP) Key financial metrics • Gross Orders in the quarter up +7% in dollars and constant currency, full year up +9% in dollars or +11% in constant currency VARIAN $M Q4 FY19 Y/Y FY19 Y/Y • Product Revenue growth driven by strong hardware and software sales Gross Orders $1,1

  16. Slide 16: Oncology Systems gross orders by geography

    Slide 16: Oncology Systems gross orders by geography

    Oncology Systems gross orders by geography APAC AMERICAS -9% Q4 Y/Y +11% Q4 Y/Y1 (-9% cc) (+11% cc) +9% FY19 Y/Y +7% FY19 Y/Y1 (+11% cc) (+7% cc) (1) In North America, Q4 orders growth of +10% and FY19 orders growth of +8% EMEA +10% Q4 Y/Y (+12% cc) +12% TTM Y/Y 16 (+16% cc)

  17. Slide 17: Proton Solutions segment (GAAP)

    Slide 17: Proton Solutions segment (GAAP)

    Proton Solutions segment (GAAP) Key financial metrics • Gross Orders growth driven by one order in the quarter for a total of four orders for the year VARIAN $M Q4 FY19 Y/Y FY19 Y/Y • Product Revenues driven by the progress made in centers under construction Gross Orders $31 425% $152 163% Revenues

  18. Slide 18: ProBeam proton therapy system sites

    Slide 18: ProBeam proton therapy system sites

    ProBeam proton therapy system sites 27 82 ProBeam Total Sites Rooms 11 41 Operational Operational Operational Centers Centers Under Development Sites Rooms1 (1) Number of Operational Rooms may not sum up to the total number on the map due to some sites having rooms which are under development. 18

  19. Slide 19: Other segment (GAAP)

    Slide 19: Other segment (GAAP)

    Other segment (GAAP) Key financial metrics VARIAN • Revenues from our Interventional Oncology $M Q4 FY19 Y/Y FY19 Y/Y business represent sales for our cryoablation, Gross Orders $17 n/a $19 n/a embolic microspheres, and microwave ablation Revenues $17 n/a $19 n/a portfolio Product $17 n/a $19 n/a Se

  20. Slide 20: FY 2020 Guidance

    Slide 20: FY 2020 Guidance

    FY 2020 Guidance varian

  21. Slide 21: Guidance for fiscal year 2020

    Slide 21: Guidance for fiscal year 2020

    Varian consolidated Guidance for fiscal year 2020 VARIAN FY18 FY19 FY20 $M Actual Actual Guidance • Guidance considers projected market growth and continued momentum of Varian’s portfolio Revenues $2,919 $3,225 $3,515B to $3,612B Y/Y % 11% 10% 9% to 12% • Guidance Assumptions Organic Y/Y %1 7% to 9%

  22. Slide 22: In summary, we are…

    Slide 22: In summary, we are…

    In summary, we are… Global leader in radiation therapy Growing our net installed base driving future recurring …Driving software and services revenues toward our vision Expanding into high growth, high margin businesses of a world without fear of cancer Winning in emerging markets with our strong va

  23. Slide 23: Appendix

    Slide 23: Appendix

    Appendix

  24. Slide 24: Non-GAAP disclosure

    Slide 24: Non-GAAP disclosure

    Non-GAAP disclosure Discussion of Non-GAAP Financial Measures This presentation includes the following non-GAAP financial measures derived from our Condensed Consolidated Statements of Earnings: non-GAAP operating earnings, non-GAAP net earnings and non-GAAP net earnings per diluted share. We define

  25. Slide 25: GAAP to non-GAAP reconciliation

    Slide 25: GAAP to non-GAAP reconciliation

    GAAP to non-GAAP reconciliation THE FOLLOWING TABLE RECONCILES GAAP AND NON-GAAP FINANCIAL MEASURES Dollars and shares in millions, except per share amounts 1Q FY19 2Q FY19 3Q FY19 4Q FY19 FY19 Non-GAAP adjustments Amortization of intangible assets and inventory step-up (1) $4.2 $6.1 $6.8 $20.0 $37.

  26. Slide 26: Total revenues by sales classification

    Slide 26: Total revenues by sales classification

    Total revenues by sales classification $M 1Q FY19 2Q FY19 3Q FY19 4Q FY19 FY19 Product revenues $400.2 $430.5 $461.3 $492.1 $1,784.1 Y/Y 9 % 9 % 26 % 10 % 14 % Service revenues $340.8 $348.9 $364.5 $386.8 $1,441.0 Y/Y 9 % 4 % 6 % 9 % 7 % Total revenues $741.0 $779.4 $825.8 $878.9 $3,225.1 Y/Y 9 % 7

  27. Slide 27: Total revenues by product type

    Slide 27: Total revenues by product type

    Total revenues by product type $M 1Q FY19 2Q FY19 3Q FY19 4Q FY19 4Q Y/Y FY19 FY19 Y/Y Hardware $347.2 $367.0 $387.9 $430.2 10 % $1,532.3 12 % Oncology Systems $313.6 $339.1 $361.7 $379.2 8 % $1,393.6 13 % Proton Solutions $33.6 $27.9 $24.2 $33.6 (15) % $119.3 (12) % Other — — $2.0 $17.4 — % $19.4 —

  28. Slide 28: Total revenues by region

    Slide 28: Total revenues by region

    Total revenues by region $M 1Q FY19 2Q FY19 3Q FY19 4QFY19 FY19 Americas revenues $350.4 $371.3 $401.2 $404.5 $1,527.4 Y/Y (2) % 9 % 17 % 2 % 6 % Y/Y – CC (2) % 10 % 17 % 2 % 7 % EMEA revenues $251.0 $261.5 $271.3 $289.6 $1,073.4 Y/Y 30 % 3 % 18 % 9 % 14 % Y/Y – CC 33 % 10 % 24 % 12 % 19 % APAC reve

  29. Slide 29: Total Oncology Systems revenues by sales classification

    Slide 29: Total Oncology Systems revenues by sales classification

    Total Oncology Systems revenues by sales classification $M 1Q FY19 2Q FY19 3Q FY19 4Q FY19 FY19 Product revenues $366.6 $402.6 $433.8 $439.4 $1,642.4 Y/Y 8 % 11 % 33 % 9 % 15 % Y/Y – CC 9 % 14 % 36 % 10 % 17 % Service revenues $335.9 $344.2 $359.1 $380.2 $1,419.4 Y/Y 8 % 3 % 6 % 8 % 6 % Y/Y – CC 9 %

  30. Slide 30: Total Oncology Systems revenues by region

    Slide 30: Total Oncology Systems revenues by region

    Total Oncology Systems revenues by region $M 1Q FY19 2Q FY19 3Q FY19 4Q FY19 FY19 Americas revenues $330.8 $357.1 $385.6 $377.8 $1,451.3 Y/Y (2) % 11 % 19 % 2 % 7 % Y/Y – CC (2) % 12 % 20 % 2 % 8 % EMEA revenues $234.5 $245.3 $256.4 $264.7 $1,000.9 Y/Y 28 % 2 % 23 % 6 % 13 % Y/Y – CC 31 % 9 % 30 % 9

  31. Slide 31: Total Proton Solutions revenues by sales classification

    Slide 31: Total Proton Solutions revenues by sales classification

    Total Proton Solutions revenues by sales classification $M 1Q FY19 2Q FY19 3Q FY19 4Q FY 19 FY19 Product revenues $33.6 $27.9 $25.5 $35.3 $122.3 Y/Y 23% (7) % (33) % (19) % (12) % Service revenues $4.9 $4.7 $5.4 $6.6 $21.6 Y/Y 172% 151% 44 % 157 % 116 % Total revenues $38.5 $32.6 $30.9 $41.9 $143.9

  32. Slide 32: Oncology Systems gross orders by region

    Slide 32: Oncology Systems gross orders by region

    Oncology Systems gross orders by region $M 1Q FY19 2Q FY19 3Q FY19 4Q FY19 FY19 Americas orders $335.9 $366.1 $357.4 $559.0 $1,618.4 Y/Y 12 % 7 % (1) % 11 % 7 % Y/Y – CC 12 % 8 % (1) % 11 % 7 % EMEA orders $218.3 $233.3 $281.1 $395.9 $1,128.6 Y/Y 15 % 17 % 8 % 10 % 12 % Y/Y – CC 17 % 25 % 13 % 12 %

  33. Slide 33: Condensed consolidated statements of cash flows

    Slide 33: Condensed consolidated statements of cash flows

    Condensed consolidated statements of cash flows $M 1Q FY19 2Q FY19 3Q FY19 4Q FY19 FY19 Net cash provided by (used in) Operating Activities $140.9 $(13.4) $126.5 $117.8 $371.8 Net earnings 103.9 88.4 29.5 89.0 310.8 Share-based compensation expense 10.5 12.5 12.2 12.7 47.9 Depreciation 12.8 13.0 12.

  34. Slide 34: Our promise: People powering victories

    Slide 34: Our promise: People powering victories

    Our promise People powering victories Imagine a world without fear of cancer. We do, every day. We innovate new technologies for treating cancer and for connecting clinical teams to advance patient outcomes. Through ingenuity we inspire new victories and empower people in the fight against cancer. W

Source: SEC EDGAR · 8-K filed Oct 23, 2019

More decks from Varian Medical Systems Inc